EXINI Diagnostics

EXINI Diagnostics is a pioneer in AI-powered medical image analysis, with a 25-year history originating from Lund University research. Its core technology provides quantitative, reproducible assessments of bone, cardiac, brain, and PSMA PET scans, with its flagship automated Bone Scan Index (aBSI) platform deployed at approximately 1,000 hospitals worldwide. Acquired by Progenics Pharmaceuticals in 2015 and subsequently by Lantheus Holdings in 2020, EXINI now operates as a key AI and software arm within a larger, integrated diagnostics and therapeutics company. Its products are commercial-stage, revenue-generating tools used to support precision oncology and other diagnostic workflows.

Proprietary AI and machine learning algorithms for automated, quantitative analysis of diagnostic medical images, including bone scans, PSMA PET, cardiac perfusion, and brain scans. Platforms transform visual scans into objective biomarkers (e.g., Bone Scan Index) and are developed as certified medical device software.

EXINI competes in the crowded AI medical imaging market against pure-play software firms (e.g., Aidoc, Zebra Medical) and the in-house AI divisions of imaging giants like GE, Siemens, and Philips. Its key differentiation is deep, disease-specific expertise in quantitative nuclear medicine biomarkers (especially for prostate cancer) and its strategic integration with Lantheus's radiopharmaceutical portfolio, creating a unique 'drug+software' synergy.